Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
14.38
+0.26 (1.84%)
At close: Apr 28, 2026, 4:00 PM EDT
14.53
+0.15 (1.04%)
After-hours: Apr 28, 2026, 5:28 PM EDT
Vor Biopharma Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 45.33, with a low estimate of 8.00 and a high estimate of 120. The average target predicts an increase of 215.23% from the current stock price of 14.38.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $32 → $31 | Strong Buy | Maintains | $32 → $31 | +115.58% | Apr 15, 2026 |
| Wedbush | Wedbush | Hold Maintains $9 → $15 | Hold | Maintains | $9 → $15 | +4.31% | Mar 31, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +247.71% | Mar 30, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $30 | Buy | Initiates | $30 | +108.62% | Mar 19, 2026 |
| Citigroup | Citigroup | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +247.71% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.31
from -70.50
EPS Next Year
-4.34
from -4.31
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.33 | -1.24 | ||||||
| Avg | -4.31 | -4.34 | ||||||
| Low | -7.64 | -8.18 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.